PCSK9 and endothelial dysfunction: Schremmer et al. [92] showed that PCSK9 inhibitors at 6 months follow-up significantly increased flow-mediated dilation (FMD), decreased aortic augmentation index and increased peripheral tissue oxygenation in the overall cohort, highlighting the positive effects of PCSK9 in endothelial dysfunction and microcirculation.